Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

NMDA Antagonists in Bipolar Depression

To see complete record on, please visit this link

Id: NCT01833897

Organisation Name: New York State Psychiatric Institute

Overal Status: Completed

Start Date: March 2013

Last Update: June 1, 2016

Lead Sponsor: New York State Psychiatric Institute

Brief Summary: The purpose of this study is to test whether ketamine and D-cycloserine can be safely and effectively used for the treatment of depression. The investigators hypothesize that ketamine will serve as a rapid acting and safe antidepressant in patients with bipolar depression, and furthermore, that D-cycloserine will serve as an effective therapy following ketamine treatment.

  • Bipolar Disorder

Total execution time in seconds: 0.30703806877136